Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer
BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i472 (Published 28 January 2016) Cite this as: BMJ 2016;352:i472Chinese translation
该文章的中文翻译
- Shervin Assassi, associate professor
- University of Texas Health Science Center at Houston, 6431 Fannin, MSB 5.266, Houston, TX 77030, USA
- shervin.assassi{at}uth.tmc.edu
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the two most common types of non-melanoma skin cancer. Epidemiological studies have indicated that the incidence of non-melanoma skin cancers is higher in patients with rheumatoid arthritis than in the general population.1 2 Further concerns exist that immunosuppression contributes to an increased prevalence of these malignancies. Specifically, organ transplantation and the concomitant use of immunosuppressive agents is strongly associated with SCC and to a lesser extent with BCC.3 4 Tumor necrosis factor (TNF) inhibitors are the most commonly used biological immunosuppressive agents for treatment of rheumatoid arthritis. Pooled data from 74 randomized controlled trials showed that TNF inhibitors were associated with an increase in risk of non-melanoma skin cancer beyond the risk associated with rheumatoid arthritis alone.5 Several large observational studies have supported this finding,6 7 but others have not.8 9 …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.